PeerView Internal Medicine CME/CNE/CPE Audio Podcast - Erika Hamilton, MD - Clarifying the Complexities of the Expanding Treatment Options for Advanced- and Early-Stage HR+/HER2- Breast Cancer

Erika Hamilton, MD - Clarifying the Complexities of the Expanding Treatment Options for Advanced- and Early-Stage HR+/HER2- Breast Cancer

01/27/23 • 100 min

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Go online to PeerView.com/YNC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Endocrine therapy, typically with an aromatase inhibitor or fulvestrant plus a CDK4/6 inhibitor, is a mainstay for the management of HR+/HER2- metastatic breast cancer, but many questions still remain about the nuances of optimal use of these and other agents in first- and later-line settings. Furthermore, a number of investigational therapies are showing great promise in HR+/HER2- advanced disease, including novel ER-targeting agents such as oral SERDs, SERMs, SERCAs, PROTACs, and others, as well as antibody–drug conjugates such as those targeting TROP2. It is essential to learn how to best integrate these options into the current treatment arsenal. CDK4/6 inhibition with adjuvant abemaciclib has also changed the standard of care for high-risk patients with earlier-stage disease, but challenges remain, such as determining which patients benefit from this approach, and how to ensure that patients stay on therapy to reduce their risk of recurrence. This PeerView educational activity, based on a recent live symposium and produced in collaboration with GRASP and Living Beyond Breast Cancer to highlight patient perspectives, pairs compelling analyses of key evidence with practically oriented discussions focused on the evolving role of various standard, new, and emerging treatment options for HR+/HER2- advanced and early breast cancer. Leading experts show how to navigate the increasing complexity of treatment in the metastatic setting, as well as the recent expansion of new therapies into early-stage disease, and discuss implications for multidisciplinary care and patient-centric best practices. Upon completion of this activity, participants should be better able to: Describe the rationale for, mechanisms of action of, and latest efficacy and safety data supporting the use of standard, new, and emerging treatment options for patients with HR+/HER2- advanced and early breast cancer, and their evolving roles in clinical practice; Develop personalized treatment plans for patients with HR+/HER2- advanced and early breast cancer that take into account all the relevant tumor-, patient-, and treatment-related factors, and include appropriately selected standard, new, or emerging treatment options in the context of clinical practice or clinical trials; Integrate a team-based, collaborative, and coordinated approach to care to educate patients with HR+/HER2- advanced and early breast cancer about new and emerging treatment options for which they may be eligible and engage patients in shared decision-making to ensure that their unique needs and preferences are taken into account when making treatment decisions.

Previous Episode

undefined - Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Fixing the Target on Aggressive Lymphoma: Guidance on the Next Phase of Integrating Targeted Agents Into MCL and DLBCL Management

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Fixing the Target on Aggressive Lymphoma: Guidance on the Next Phase of Integrating Targeted Agents Into MCL and DLBCL Management

Go online to PeerView.com/YVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Across B-cell non-Hodgkin lymphoma settings, the use of targeted agents has in many instances eclipsed the use of standard chemoimmunotherapy. In more aggressive B-cell lymphomas, including in mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL), progress with targeted therapy has been slower. However, new evidence with BTK inhibitors in MCL and DLBCL indicates that they may boost efficacy when added to proven therapeutic platforms or when used in disease subtypes defined by molecular (eg, activated B-cell) features. At PeerView’s recent “Clinical Consults” event, experts explored the implications of these new developments—highlighting evidence supporting novel BTKi-based combinations, BTKi regimens in diverse DLBCL patient populations, and the important safety considerations necessary for successful use of targeted agents in MCL and DLBCL. Upon completion of this activity, participants should be better able to: Cite current evidence on the efficacy of targeted agent classes in aggressive lymphoma, including BTK, BCL-2, and XPO1 inhibitors as monotherapy or as part of novel combinatorial strategies across MCL and DLBCL treatment settings; Integrate personalized therapeutic platforms with targeted components into the management of patients with MCL or DLBCL, including as first-, second-, or third-line care; and Manage the unique suite of adverse events associated with the single-agent and combination use of targeted agent classes in the setting of aggressive lymphoma

Next Episode

undefined - Nikhil C. Munshi, MD - The Road to Remission in Multiple Myeloma: Expert Guidance on Using BCMA-Targeted Options to Enhance Clinical Outcomes

Nikhil C. Munshi, MD - The Road to Remission in Multiple Myeloma: Expert Guidance on Using BCMA-Targeted Options to Enhance Clinical Outcomes

Go online to PeerView.com/KTZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you fully prepared to safely integrate BCMA-targeting options into the care plan for your relapsed/refractory multiple myeloma (MM) patients, including treatment with antibodies, bispecific agents, and CAR-T cell therapy? Find out in this expert-led MasterClass and Case Forum recorded at the Annual Hematology Meeting. Watch our experts as they offer learners guidance on the “road to remission” in MM, and hear how recent advances with BCMA-targeted therapies can directly lead to enhanced outcomes in the most challenging treatment settings. Throughout, the experts also provide case-based guidance on therapy selection with BCMA antibodies and CAR-T therapy, and illustrate how evidence-based practice can optimize delivery of care in pretreated disease. Get on the “road to remission” for your patients, and receive CME/MOC credit today! Upon completion of this activity, participants should be better able to: State the current evidence and rationale that support the treatment roles of novel BCMA-targeting platforms, including antibody-drug conjugates, bispecifics, and CAR-T therapy, in relapsed/refractory disease; Select personalized, evidence-based regimens with novel anti-BCMA options based on patient preference, disease prognosis, and functional status, among others; and Develop strategies for addressing practical aspects of BCMA-targeted therapy in RRMM, including issues related to dosing/scheduling, patient counseling, and unique safety considerations such as cytopenias, infusion-related events, ocular toxicity, and cytokine release syndrome, among others.